SGMT
Sagimet Biosciences Inc - Class A (SGMT)
Healthcare • NASDAQ • $7.71+0.92%
- Symbol
- SGMT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $7.71
- Daily Change
- +0.92%
- Market Cap
- $476.11M
- Trailing P/E
- N/A
- Forward P/E
- -5.22
- 52W High
- $11.41
- 52W Low
- $3.08
- Analyst Target
- $28.50
- Dividend Yield
- N/A
- Beta
- 3.64
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headqu…
Company websiteResearch SGMT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.